PIPELINE

By dedicating an independent company to each asset, Dauntless offers a faster and more capital efficient way to advance clinical candidates. Each company has the benefit of Dauntless’ expertise across the drug development continuum.

Asset Company Pre-Clinical Clinical Development
Safety Proof-of-Concept Pivotal
Dauntless 1

DP1038 Intranasal Octreotide
acromegaly / neuroendocrine tumors / CID
Dauntless 2

DP2018 Undisclosed Asset
oncology
Dauntless 3

Coming Soon
Asset Company Phase
Dauntless 1
DP1038 Intranasal Octreotide		 Proof-of-Concept
Dauntless 2
DP2018 Undisclosed Asset		 Pre-Clinical
Dauntless 3
Coming Soon

Dauntless 1

Download DP1038 Poster

Developing a non-injectable somatostatin analog alternative for patients. DP1038 is a short-acting octreotide formulation delivered as a nasal mist that is not inhaled.

Octreotide, a somatostatin analog, is an inhibitor of growth hormone that is administered solely by injection in approved products, and is used as first-line pharmacotherapy for two orphan diseases, acromegaly and neuroendocrine tumors, with utility in several gastrointestinal disorders including chemotherapy-induced diarrhea (CID).

The current market for somatostatin analogs exceeds $2 billion and is dominated by products that are administered by health care professionals. Limitations of long-acting somatostatin analogs include painful injection site reactions and nodules from very large injection volumes and needles, and breakthrough symptoms when octreotide levels are too low to adequately treat the patient.

DP1038 is being developed for patients who desire a non-invasive alternative or who are not adequately controlled on long-acting formulations and can benefit from short-acting pharmacotherapy.

DP1038 leverages patented Intravail® technology developed by Aegis Therapeutics LLC for enhanced intranasal absorption.

Dauntless 2

DP2018 is an oncology asset currently in pre-clinical development with IND filing expected in early 2018.

Dauntless 3

Coming soon…